Prognostic relevance of Tiam1 protein expression in prostate carcinomas

R Engers*,1, M Mueller2, A Walter1, JG Collard3, R Willers4 and HE Gabbert1

1Institute of Pathology, Heinrich-Heine-University, Moorenstrasse 5, Duesseldorf D-40225, Germany; 2Department of Urology, Heinrich-Heine-University, Moorenstrasse 5, Duesseldorf D-40225, Germany; 3The Netherlands Cancer Institute, Department of Cell Biology, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; 4Department of Computational Statistics, Heinrich-Heine-University, Moorenstrasse 5, Duesseldorf D-40225, Germany

The Rac-specific guanine nucleotide exchange factor, Tiam1, plays a major role in oncogenicity, tumour invasion and metastasis but its usefulness as a prognostic marker in human cancer has not been tested yet. In the present study, Tiam1 expression was analysed in benign secretory epithelium, pre-neoplastic high-grade prostatic intraepithelium neoplasia (HG-PIN) and prostate carcinomas of 60 R0-resected radical prostatectomy specimens by semiquantitative immunohistochemistry. Tiam1 proved significantly overexpressed in both HG-PIN (P<0.001) and prostate carcinomas (P<0.001) when compared to benign secretory epithelium. Strong Tiam1 overexpression (i.e. ≥3.5-fold) in prostate carcinomas relative to the respective benign prostatic epithelium was statistically significantly associated with disease recurrence (P=0.016), the presence of lymph vessel invasion (P=0.031) and high Gleason scores (GS) (i.e. ≥7) (P=0.044). Univariate analysis showed a statistically significant association of strong Tiam1 overexpression with decreased disease-free survival (DFS) (P=0.03). This prognostic effect of strong Tiam1 overexpression remained significant in multivariate analysis including preoperative prostate-specific antigen levels, pT stage, and GS (relative risk = 3.75, 95% confidence interval = 1.06–13.16; P=0.04). Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.

British Journal of Cancer (2006) 95, 1081–1086. doi:10.1038/sj.bjc.6603385 www.bjcancer.com

Published online 26 September 2006

© 2006 Cancer Research UK

Keywords: Tiam1; Rac; prognosis; prostate cancer; proliferation

Prostate cancer is a leading cause of cancer death in men in North America and Western Europe. However, as compared to the high general risk of prostate cancer (one in six), the risk of death owing to prostate cancer is one in 30 (Jemal et al, 2003), indicating that only a fraction of cases would lead to cancer-related death if left untreated. Consequently, there is a great need for markers, which accurately predict the risk of disease progression in patients with prostate cancer and thus allow appropriate treatment planning. However, prognostic markers typically used so far, including tumour stage, Gleason score (GS), and the serum level of prostate-specific antigen (PSA) are not sufficiently precise to do so (Ross et al, 2003).

The guanine nucleotide exchange factor, Tiam1, specifically activates the Rho-like GTPase Rac (Michiels et al, 1995) and Tiam1-Rac signaling affects cell migration (Hordijk et al, 1997; Sander et al, 1998), invasion (Michiels et al, 1995; Keely et al, 1997; Engers et al, 2001), and metastasis (Habets et al, 1994) of tumour cells. Moreover, Tiam1 and Rac have been implicated in oncogenic transformation of cells. Thus, N-terminal truncation of the Tiam1 protein activates its oncogenic potential in NIH3T3 cells (van Leeuwen et al, 1995). Moreover, Rac is essential for Ras-induced transformation of these cells (Qiu et al, 1995) and in line with this, Tiam1-deficient mice are resistant to the development of Ras-induced skin tumours (Malliri et al, 2002). In addition, we identified several Tiam1 mutations in a significant proportion of human renal cell carcinomas, one of which proved sufficient to transform NIH3T3 cells in vitro (Engers et al, 2000). Despite these functions the potential prognostic relevance of Tiam1 expression in human tumours has not been investigated yet.

In the present study, we have analysed Tiam1 expression in benign secretory epithelium, high-grade prostatic intraepithelium neoplasia (HG-PIN), and prostate carcinomas by semiquantitative immunohistochemistry. We found that Tiam1 is significantly overexpressed in almost all prostate carcinomas and HG-PIN lesions when compared to the corresponding benign secretory epithelium. Moreover, in multivariate analysis, the extent of Tiam1 overexpression relative to the corresponding benign epithelial cells proved to be an independent predictor of decreased disease-free survival (DFS) for patients with prostate cancer.

MATERIALS AND METHODS

Patients

In the present study, we investigated Tiam1 expression by semiquantitative immunohistochemistry in 60 patients with R0-resected prostate cancer, who underwent radical prostatectomy at
Tiam1 overexpression in prostate cancer

R Engers et al

Pathological and immunohistochemical evaluation

All tumours were staged using the Tumour-Node-Metastasis (TNM) system (Sobin and Wittekind, 2002) and graded according to the system described by Gleason (1988). Moreover, all tumours were evaluated for blood vessel invasion (BVI), lymph vessel invasion (LVI), perineural invasion (PNI), and the presence of HG-PIN by the study pathologist. For immunohistochemistry representative 5-μm sections of paraffin-embedded tissue specimens were subjected to heat-induced antigen retrieval and subsequently incubated with a Tiam1-specific rabbit polyclonal antibody (anti-DH, (Habets et al, 1994; Malliri et al, 2002, 2006) dilution 1: 100) using a Ventana BenchMark immunohistochemical autostainer (Ventana Medical Systems, Munich, Germany) including the respective solutions according to the manufacturer’s instructions. As a negative control, representative sections were subjected to the same immunostaining procedure except for the fact that the primary antibody was omitted. As a positive control, paraffin-embedded tumour spheroids of Tiam1-transfected renal carcinoma cells (Engers et al, 2001) were used. The specificity of the Tiam1 antibody used in this study has previously been demonstrated (Habets et al, 1994; Malliri et al, 2002). For quantification, the percentage of positive cells was divided into five groups: 0, 0%; 1, 1–10%; 2, 11–50%; 3, 51–80%; and 4, >80%. Moreover, a scale from 0 (no staining) to 3 (strong immunoreactivity) was assigned to staining intensity. Immunoreactive scores (range, 0–12) were calculated by multiplying percentage score of positive cells times staining intensity. Immunoreactive scores in benign secretory epithelial cells were significantly stronger than absolute immunoreactive scores. As in all cases analysed semiquantitatively immunohistochemistry significant differences were found in the expression of Tiam1 between benign and premalignant (i.e. HG-PIN) or benign and malignant prostatic epithelial cells (i.e. cancer), respectively, we only observed a single lymph node micrometastasis was observed. All patients were free of distant metastases at the time of radical prostatectomy. Gleason scores ranged from 5 to 10 with GS <7 in 11 patients (18%) and GS ≥7 in 49 patients (82%). PNI was observed in 46 patients (77%), LVI in six patients (10%), and BVI in two patients (3%).

RESULTS

Histological tumour characterisation

Based on histological examination 37 tumours (62%) were categorised as pT2 (organ-confined tumours) and 23 tumours (38%) as pT3 (tumours with extraprostatic extension). In one patient (2%) a single lymph node micrometastasis was observed. All patients were free of distant metastases at the time of radical prostatectomy. Gleason scores ranged from 5 to 10 with GS <7 in 11 patients (18%) and GS ≥7 in 49 patients (82%). PNI was observed in 46 patients (77%), LVI in six patients (10%), and BVI in two patients (3%).

Tiam1 is significantly stronger expressed in high-grade prostatic intraepithelium neoplasia lesions and prostate carcinomas than in the corresponding benign prostatic glands

By semiquantitative immunohistochemistry significant differences in Tiam1 expression became evident between benign prostatic glands on the one hand and HG-PIN lesions and prostate cancer on the other hand. Thus, Tiam1 proved significantly stronger expressed in 54 out of 55 (98.2%) HG-PIN lesions than in the respective normal counterpart (P < 0.001) (Figure 1A and C). Similarly 58 out of 60 (96.7%) prostate carcinomas exhibited significantly stronger Tiam1 expression levels than the respective benign secretory epithelium (P < 0.001) (Figure 1B and C). On average, Tiam1 expression levels were 3.75-fold higher in prostate cancer and 3.6-fold higher in HG-PIN lesions, respectively, than in the corresponding benign secretory epithelial cells (Figure 1C). However, no difference was seen between Tiam1 expression in prostate cancer and HG-PIN lesions (Figure 1C). In general Tiam1 expression in prostate cancer was very homogeneous and did not differ between different Gleason patterns or different tumour focussing on the same slide.

In addition to significant differences in Tiam1 expression between benign and premalignant (i.e. HG-PIN) or benign and malignant prostatic epithelial cells (i.e. cancer), respectively, we also observed differences in Tiam1 expression between normal non-epithelial cells, including inflammatory cells, fibromuscular stromal cells, and ganglion cells. Although semiquantitative analysis was not applied to these cell types, we constantly observed that amongst the inflammatory cells Tiam1 expression was markedly stronger in plasma cells than in lymphocytes and histiocytes, and that neutrophilic granulocytes appeared to be negative (Figure 1D). Moreover, Tiam1 was strongly expressed by ganglion cells (Figure 1E), whereas fibromuscular stromal cells failed to express Tiam1 (Figure 1A and B).

Evaluating potential associations between Tiam1 protein expression in prostate cancer and different clinicopathological factors

To analyse potential associations between the extent of Tiam1 overexpression in prostate cancer and different clinicopathological factors (age, preoperative PSA, LVI, BVI, PNI, pT, pN, GS, and disease recurrence) Tiam1 immunoreactive ratios (e.g. Tiam1 expression levels in prostate cancer relative to those in the corresponding benign secretory epithelial cells), were
dichotomised into two categories (<3.5-fold vs ≥3.5-fold). The cutoff level of 3.5-fold rather than 3.75-fold (the latter of which represents the mean extent of Tiam1 overexpression in our cohort) was chosen for two reasons: (i) 3.5-fold is more convenient in terms of a potential application in routine pathology and (ii) only one patient was affected by this modification. Given a mean preoperative PSA level of 14.4 ng ml⁻¹ in our cohort, preoperative PSA levels were dichotomised into <15 vs ≥15 ng ml⁻¹. Gleason scores were subdivided into <7 vs ≥7, and pT stage into organ-confined tumours (pT2) vs tumours with extraprostatic extension (pT3). Other parameters such as LVI, BVI, PNI, and pN were categorised into present vs not present. As shown in Table 1, the extent of Tiam1 overexpression in prostate carcinoma was statistically significantly associated with the presence of LVI (P = 0.031), GS ≥7 (P = 0.044) and with disease recurrence (P = 0.016), but not with any other parameter.

Evaluating the prognostic relevance of Tiam1 overexpression and different clinico-pathological factors in prostate cancer

Univariate analysis As the patients in this cohort had variable follow-up times between 24 and 173 months, the Cox proportional hazards model and single-parameter analysis was used to determine the prognostic significance of each of the different clinico-pathological factors (i.e. age, preoperative PSA, LVI, BVI, PNI, pT, pN, and GS) as well as Tiam1 overexpression. As shown in Table 2, age, LVI, BVI, PNI, and pN did not significantly predict...
Table 1 Clinopathologic features of Tiam1 overexpression in prostate cancer

| Factor          | Tiam1 overexpression (n = 26) No. (%) | Tiam1 overexpression (n = 34) No. (%) | P-valueb |
|-----------------|--------------------------------------|--------------------------------------|----------|
| Age (y)         |                                       |                                       |          |
| <65             | 13 (22)                              | 13 (22)                              | 0.435    |
| ≥65             | 13 (22)                              | 21 (35)                              |          |
| Preoperative PSAa (ng/ml−1) |                                       |                                       |          |
| <15             | 18 (31)                              | 19 (32)                              | 0.423    |
| ≥15             | 8 (14)                               | 14 (24)                              |          |
| Disease recurrencea |                                       |                                       |          |
| No              | 20 (38)                              | 16 (30)                              | 0.016*   |
| Yes             | 3 (6)                                | 14 (26)                              |          |
| LVI             |                                       |                                       |          |
| No              | 26 (43)                              | 28 (47)                              | 0.031*   |
| Yes             | 0 (0)                                | 6 (10)                               |          |
| BVI             |                                       |                                       |          |
| No              | 25 (42)                              | 33 (55)                              | 1.0      |
| Yes             | 1 (2)                                | 1 (2)                                |          |
| pN              |                                       |                                       |          |
| No              | 6 (10)                               | 8 (13)                               | 1.0      |
| Yes             | 20 (33)                              | 26 (43)                              |          |
| pT              |                                       |                                       |          |
| pT2             | 18 (30)                              | 19 (32)                              | 0.422    |
| pT3             | 8 (13)                               | 15 (25)                              |          |
| pN              |                                       |                                       |          |
| pN0             | 26 (43)                              | 33 (55)                              | 1.0      |
| pNI             | 0 (0)                                | 1 (2)                                |          |
| GS              |                                       |                                       |          |
| <7              | 8 (13)                               | 3 (5)                                | 0.044*   |
| ≥7              | 18 (30)                              | 31 (52)                              |          |

BVI: blood vessel invasion; GS: Gleason score; LVI: lymph vessel invasion; PNI: perineural invasion; PSA: prostate-specific antigen; y: years. *Statistically significant. *Because of rounding percentages may not equal 100%. *Fisher’s exact test, two sided. Preoperative PSA levels were available for 59 out of 60 patients. *Appropriate follow-up was available for 53 out of 60 patients.

Table 2 Univariate analysis of pre- and postoperative parameters as well as Tiam1 overexpression

| Parameter          | χ²     | P-value | Hazard ratio | 95% CI |
|--------------------|--------|---------|--------------|--------|
| Age                | 1.658  | 0.202   | 1.058        | 0.970–1.155 |
| Preoperative PSA   | 4.174  | 0.044*  | 1.035        | 1.001–1.070 |
| pT                 | 9.451  | 0.006*  | 5.805        | 1.657–20.339 |
| pN                 | 3.726  | 0.091   | 6.098        | 0.750–50 |
| GS                 | 12.685 | 0.001*  | 2.121        | 1.369–3.286 |
| pNI                | 2.105  | 0.164   | 2.907        | 0.646–13.158 |
| BVI                | 0.592  | 0.612   | 21.639       | 0.000–3126101 |
| LVI                | 2.323  | 0.142   | 2.604        | 0.725–9.346 |
| Tiam1 overexpression | 5.531  | 0.030*  | 3.5          | 1.15–13.89 |

CI, confidence interval. *Statistically significant. Cox proportional hazard model and single parameter analysis was used to determine the prognostic significance of age, preoperative PSA, LVI (+/-), BVI (+/-), PNI (+/-), pT stage (pT3/pT2), pN stage (pN1/pN0), GS, and Tiam1 overexpression (≥3.5-fold)<3.5-fold. Age, preoperative PSA and GS were used as continuous variables.

Diseases. More specifically, the mean DFS time of patients with strong Tiam1 overexpression (≥3.5-fold) in prostate carcinomas was 98 months (95% confidence interval (CI) = 77–119), whereas the mean DFS time of patients with weak Tiam1 overexpression (<3.5-fold) was 136 months (95% CI = 118–154).

Multivariate analysis To determine the smallest number of parameters that could jointly predict disease recurrence in our cohort of patients, the Cox proportional hazard model and stepwise selection analysis was used. When all parameters with significant prognostic impact in univariate analysis (i.e. preoperative PSA, pT stage, GS, and the extent of Tiam1 overexpression) were included in the model, only pT stage (P = 0.028, hazard ratio = 4.61), GS (P = 0.019, hazard ratio = 1.80), and the extent of Tiam1 overexpression (P = 0.04, hazard ratio = 3.75) reached statistical significance in predicting decreased DFS (Table 3). Moreover, including the extent of Tiam1 overexpression in the analysis further classified the pT stage and GS groups into high-and low-risk patients. To demonstrate the joint effects of Tiam1 overexpression and pT stage or Tiam1 overexpression and GS, respectively, on disease recurrence, Kaplan–Meier analysis was performed. As shown in Figure 2A, in both pT stage subgroups (pT2 and pT3) patients with strong Tiam1 overexpression (i.e. ≥3.5-fold) had a significantly worse prognosis than patients with weak Tiam1 overexpression (i.e. <3.5-fold) (P < 0.001). Thus, the highest probability of disease recurrence was found in patients with strong Tiam1 overexpression and pT3 stage, whereas individuals with weak Tiam1 overexpression and pT2 stage had the lowest probability of recurrence. Likewise, when the cohort was stratified into GS <7 vs GS ≥7, patients with strong Tiam1 overexpression and GS ≥7 had the highest probability of disease recurrence, followed by patients with weak Tiam1 overexpression and GS ≥7 (Figure 2B). The least probability of disease recurrence was found in the subgroup of GS <7. This subgroup, however, was restricted to 11 patients and no disease recurrence was observed during a median follow-up time of 72 months (range, 36–135 months). Thus, in the subgroup of GS <7 a prognostic impact of Tiam1 overexpression could not be established, at least not for the restricted number of patients and the given mean follow-up time.

DISCUSSION

In the present study, we show for the first time that in almost all prostate carcinomas the Tiam1 protein is significantly stronger expressed than in the corresponding benign prostate epithelial cells. In addition, strong Tiam1 overexpression (i.e. ≥3.5-fold) in prostate cancer relative to the corresponding benign epithelial cells is statistically significantly associated with decreased DFS after radical prostatectomy both in univariate analysis and in multivariate analysis, including several factors typically used to predict the prognosis of patients with prostate cancer. Therefore, our results suggest that strong Tiam1 overexpression is a new and
independent predictor of disease recurrence for patients with prostate cancer and that tumours with strong Tiam1 overexpression require more aggressive treatment.

The cohort of our study is restricted to 60 patients with prostate cancer, including 53 patients with appropriate follow-up. Despite its limited size, the strength of this cohort is its restriction to R0-resected tumours, because thus disease recurrence indeed reflects tumour aggressiveness (i.e. the development of metastasis) rather than being merely the result of incomplete surgical excision of the primary tumour. Furthermore, our cohort is representative, as evidenced by the fact that well-established prognostic factors, including preoperative PSA level, pT stage, and GS, also significantly predicted disease recurrence in our study. Of these, only preoperative PSA lost its prognostic impact in multivariate analysis, when combined with the extent of Tiam1 overexpression in prostate cancer. Thus, the smallest number of parameters that could jointly predict disease recurrence included pT stage, GS, and the extent of Tiam1 overexpression. Moreover, Kaplan–Meier analysis showed that prostate cancer patients with pT3 stage and GS ≥ 7, respectively, could be further classified based on the extent of Tiam1 overexpression in their prostate cancer specimens to predict disease recurrence more accurately. Only in the subgroup of GS < 7 a prognostic effect of the extent of Tiam1 overexpression could not be established despite a mean follow-up time of 6 years. This, however, does not exclude a prognostic relevance of the extent of Tiam1 overexpression in this subgroup. It has been shown that the overall postoperative risk of patients with GS < 7 tumours to develop disease recurrence at 5 years is only about 1–2% (Epstein et al., 1996). Consequently, the mean follow-up time of 6 years and the number of patients (n = 11) in the GS < 7 subgroup of our cohort are not likely to be sufficient to allow the detection of new prognostic markers in this subgroup. So far, we have evaluated Tiam1 expression only in radical prostatectomy specimens, but if this marker is to be used as part of a pretreatment decision-making tool, its predictive power has to be validated in studies on biopsy specimens as well.

Increased Tiam1 expression was observed in almost all prostate carcinomas when compared to the corresponding benign epithelial cells and the distribution of Tiam1 staining is reminiscent of that reported for alpha-methyl CoA racemase (Jiang et al., 2001; Zhou et al., 2004). In contrast to alpha-methyl CoA racemase, Tiam1 expression was seen in benign glands more regularly, but expression levels were usually low and only a fraction of benign epithelial cells was positive. This suggests that similar as reported for alpha-methyl CoA racemase, strong Tiam1 expression could be used as an adjunct for the diagnosis of prostate cancer in difficult cases such as small foci in prostate needle biopsies. Nevertheless, further studies on biopsy specimens are required to finally evaluate the diagnostic potential of strong Tiam1 expression in resolving an atypical diagnosis on prostate needle biopsies.

Interestingly, significantly increased Tiam1 expression levels were not only observed in prostate cancer, but also in almost all preneoplastic HG-PIN lesions, indicating that increased Tiam1 expression occurs early in prostate carcinoma development. Although the molecular mechanism, causing increased Tiam1 expression in HG-PIN lesions and prostate cancer, has yet to be determined, there are indications that it might result at least in part from increased Wnt/β-catenin signaling. The Wnt/β-catenin signaling pathway plays a central role in colon cancer development (for review see Oving and Clevers (2002)), but in several studies aberrant activation of Wnt/β-catenin signaling has also been implicated in the formation of PIN-like proliferative lesions as well as in prostate cancer progression (for review see Mimeault and Batra (2006); Yardy and Brewster (2005)). Interestingly, we recently identified Tiam1 as a Wnt-responsive gene that is upregulated in intestinal and colon tumours, and by comparing tumour development in APC mutant multiple intestinal neoplasia (Min) mice expressing or lacking Tiam1, we found that Tiam1 deficiency significantly reduces the formation and growth of intestinal polyps in vivo (Malliri et al., 2006). Given these results and the established oncogenic/transforming potentials of Tiam1 and its downstream target Rac in other cell types, one might speculate that a cross-talk between Wnt/β-catenin and Tiam1-Rac signaling plays a major role in the development of prostate cancer, although the underlying molecular mechanism remains to be determined. Tiam1 and Rac stimulate several important signaling pathways, including the p38 mitogen-activated protein kinase (p38 MAPK), the c-Jun N-terminal kinase, and the extracellular signal-regulated kinase pathways (Cosos et al., 1995; Zhang et al., 1995; Frost et al., 1996), which are known to regulate gene transcription. Therefore, it is conceivable that increased Tiam1 expression

Figure 2 Kaplan–Meier analysis was performed after stratifying the data (extension) and Tiam1 strong (s)/weak (w) and (A) as pT2 (organ-confined tumours)/pT3 (tumours with extraprostatic extension) and Tiam1 strong (s)/weak (w) and (B) as GS ≤ 7/≥ 7 and Tiam1 strong (s)/weak (w). Statistical analysis was performed by means of the two-sided log-rank test.

© 2006 Cancer Research UK
might induce transcription of distinct oncogenes and/or inhibit transcription of distinct tumour suppressor genes, which consequently contributes to oncogenic transformation. In conclusion, the present study with up to 14.4-year follow-up shows that strong Tiam1 overexpression in prostate cancer relative to the corresponding benign prostate epithelial cells correlates with aggressive disease and is an independent prognostic indicator of disease recurrence. Validation of this study involving a relatively small number of patients will establish the independent prognostic potential of strong Tiam1 overexpression in predicting disease recurrence. Moreover, it will be interesting to analyse its predictive power in further studies on biopsy specimens as well as in other tumour cell types.

ACKNOWLEDGEMENTS
We thank S Schneeloch, C Feldhoff, M Ringler, and R van der Kamen for their excellent technical assistance. Some of the results are part of the medical thesis of A Walter.

REFERENCES

Adam L, Vadlamudi RK, McCrea P, Kumar R (2001) Tiam1 overexpression potentiates hergulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 276: 28443 – 28450

Beck T, Weikel W, Brumm C, Wilkens C, Pollow K, Knappstein PG (1994) Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 53: 220 – 227

Costa OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS (1995) The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81: 1137 – 1146

Engers R, Springer E, Michiels F, Collard JG, Gabbert HE (2001) Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression. J Biol Chem 276: 41889 – 41897

Engers R, Zwaaka TP, Gohr L, Weber A, Gerharz CD, Gabbert HE (2000) Tiam1 mutations in human renal-cell carcinomas. Int J Cancer 88: 369 – 376

Epstein JJ, Partin AW, Sauvageot J, Walsh PC (1996) Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20: 286 – 292

Frost JA, Xu S, Hutcheson MR, Marcus S, Cobb MH (1996) Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members. Mol Cell Biol 16: 3707 – 3713

Gleason DF (1988) Histological grade, clinical stage, and patient age in prostate cancer. NCI Monogr 7: 15 – 18

Habets GG, Scholtes EH, Zuidgeest D, van der Kammen RA, Stam JC, Berns A, Collard JG (1994) Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP-exchangers for Rho-like proteins. Cell 72: 537 – 549

Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LC, Collard JG (1997) Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. Science 278: 1464 – 1466

Jenal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53: 5 – 26

Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcock JS, Rathnaswami P, Reed SG, Xu J, Fanger GR (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25: 1397 – 1404

Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV (1997) Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI3K. Nature 390: 632 – 636

Malliri A, Rygiel TP, van der Kammen RA, Song JY, Engers R, Hurlstone AF, Clevers H, Collard JG (2006) The Rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J Biol Chem 281: 543 – 548

Malliri A, van der Kammen RA, Clark K, van d V, Michiels F, Collard JG (2002) Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417: 867 – 871

Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG (1995) A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375: 338 – 340

Mimeault M, Batra SK (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1 – 22

Minard ME, Kim LS, Price JE, Gallick GE (2004) The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 94: 21 – 32

Oving IM, Clevers HC (2002) Molecular causes of colon cancer. Eur J Clin Invest 32: 448 – 457

Price LS, Collard JG (2001) Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin Cancer Biol 11: 167 – 173

Qiu RG, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for Rac in Ras transformation. Nature 374: 457 – 459

Ross JS, Jennings TA, Nazeret T, Sheehan CE, Fisher HA, Kauffman RA, Anwar S, Kallakury BV (2003) Prognostic factors in prostate cancer. Am J Clin Pathol 120(Suppl): S85 – S100

Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F, Collard JG (1998) Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol 143: 1385 – 1398

Sobin LH, Wittekind CH (2002) TNM Classification of Malignant Tumours. John Wiley & Sons: Hoboken, New Jersey

van Leeuwen FN, van der Kammen RA, Habets GG, Collard JG (1995) Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene 11: 2215 – 2221

Yardi GW, Brewster SF (2005) Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 8: 119 – 126

Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM (1995) Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 270: 23934 – 23936

Zhou M, Aydin H, Kanane H, Epstein JI (2004) How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 28: 239 – 243